End-of-day quote
04/09/2026
5-day change
1st Jan Change
85.10 NOK
+0.12%
0.00%
-14.90%
Market Cap
513M
55.32M
47.69M
45.11M
40.91M
76.21M
5.29B
77.13M
535M
206M
2.69B
208M
203M
8.44B
P/E 2023 *
-
P/E 2024
3.26x Enterprise Value
264M
28.5M
24.57M
23.24M
21.08M
39.26M
2.72B
39.73M
276M
106M
1.38B
107M
105M
4.35B
EV / Sales 2023
-1.24x
EV / Sales 2024
0.4x Free-Float
6.26%
Yield 2023 *
-
Yield 2024
32.5%
Day Week Month
Close Mountain
17/06
Norda ASA announces Annual dividend, payable on June 25, 2026
CI
13/05/25
Norda ASA announces Annual dividend, payable on May 22, 2025
CI
06/05/25
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2024
CI
01/11/23
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022
CI
16/06/22
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
21/06/21
Norda Asa Reports Earnings Results for the Full Year Ended December 31, 2020
CI
23/05/13
Norda ASA Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2013
CI
09/04/13
Norda ASA Reports Unaudited Net Debt Results as of December 31, 2012
CI
09/04/13
Norda ASA Appoints Scient Frode Westvold as CEO
CI
28/02/13
Norda ASA Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2012
CI
31/10/12
Norda ASA Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012
CI
12/10/12
Norda ASA Obtains NOK 35 Million Line of Credit from a Norwegian Bank
CI
29/08/12
Norda ASA Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012
CI
1 day +0.12%
Current month +0.12%
1 month -1.50%
3 months -1.50%
Current year -14.90%
1 month
85
85.1
Current year
81
86.4
1 year
81
100
3 years
41
100
5 years
41
100
10 years
8
100
Manager
Title Age Since
Chief Executive Officer
-
08/04/2013
Director
Title Age Since
Chairman
54
31/01/2014
Director/Board Member
68
20/06/2013
Director/Board Member
-
-
2023 2024 Net sales
86.92M
9.37M
8.08M
7.64M
6.93M
12.91M
895M
13.06M
90.63M
34.91M
455M
35.19M
34.41M
1.43B
372M
40.09M
34.56M
32.69M
29.65M
55.22M
3.83B
55.89M
388M
149M
1.95B
151M
147M
6.12B
Net income
31.17M
3.36M
2.9M
2.74M
2.49M
4.63M
321M
4.69M
32.5M
12.52M
163M
12.62M
12.34M
513M
126M
13.58M
11.71M
11.07M
10.04M
18.7M
1.3B
18.93M
131M
50.58M
659M
50.99M
49.86M
2.07B
Net Debt
-311M
-33.55M
-28.93M
-27.36M
-24.81M
-46.22M
-3.21B
-46.78M
-325M
-125M
-1.63B
-126M
-123M
-5.12B
-249M
-26.82M
-23.13M
-21.87M
-19.84M
-36.95M
-2.56B
-37.4M
-259M
-99.93M
-1.3B
-101M
-98.51M
-4.09B
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-6pm CET
DAILY FREE LIMIT REACHED
To continue browsing, Sign up!
Personal watchlists and screeners
Access the "Discovery" Stock Screener (covering 30,000 companies)
Create your free account
Become a member and join over 1 million active investors
Already have an account?
Log in
Select your edition
All financial news and data tailored to specific country editions